Odronextamab

Detailed article on Odronextamab, a bispecific monoclonal antibody

Odronextamab
[[File:|frameless|220px|alt=|]]
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number	123456-78-9
PubChem
DrugBank
ChemSpider
KEGG

Odronextamab is a bispecific monoclonal antibody designed for the treatment of certain types of B-cell non-Hodgkin lymphoma. It is currently under investigation in clinical trials and has shown promise in targeting and eliminating cancerous B-cells by engaging the body's own immune system.

Mechanism of Action

Odronextamab is engineered to bind simultaneously to CD20 on B-cells and CD3 on T-cells. This dual binding brings T-cells into close proximity with B-cells, facilitating the T-cell-mediated killing of the B-cells. The engagement of CD3 on T-cells activates them, leading to the release of cytotoxic granules and cytokines that induce apoptosis in the target B-cells.

Clinical Development

Odronextamab is being developed by Regeneron Pharmaceuticals. It is currently in phase 2 clinical trials for the treatment of relapsed or refractory B-cell non-Hodgkin lymphoma. Early clinical data have demonstrated significant anti-tumor activity, with manageable safety profiles.

Pharmacokinetics

The pharmacokinetics of odronextamab involve its distribution, metabolism, and excretion. As a monoclonal antibody, it is expected to have a long half-life, allowing for less frequent dosing. The drug is administered intravenously, and its clearance is primarily through proteolytic catabolism.

Adverse Effects

Common adverse effects observed in clinical trials include cytokine release syndrome (CRS), which is a common side effect of T-cell engaging therapies. Other side effects may include infusion-related reactions, fatigue, and hematological toxicities.

Regulatory Status

As of the latest update, odronextamab has not yet received approval from major regulatory agencies such as the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA). It remains an investigational drug.

Research and Future Directions

Ongoing research is focused on optimizing the dosing regimen and minimizing adverse effects. Combination therapies with other agents are also being explored to enhance efficacy and overcome resistance mechanisms.

Also see

• Monoclonal antibody therapy
• Bispecific monoclonal antibodies
• CD20
• CD3
• B-cell non-Hodgkin lymphoma